Introduction
============

Recently, the beneficial clinical efficacy of traditional Japanese Kampo medicine has been reported when applied for the treatment of diseases that are insufficiently cured with Western medical approaches. Yokukansan (YKS) originates from the traditional Chinese medicine *Yi-Gan-San* and is one of the Kampo prescriptions approved by the Japanese Ministry of Health, Labor, and Welfare as a remedy for neurosis, insomnia, as well as night crying and irritability for children. It is composed of seven dried medicinal herbs: *Atractylodes lancea rhizome* (*Atractylodes lancea* De Candolle, Compositae); *Poria sclerotium* (*Poria cocos* Wolf, Polyporaceae); *Cnidium rhizome* (*Cnidium officinale* Makino, Umbelliferae); *Uncaria hook* (*Uncaria rhynchophilla* Miquel, Rubiaceae); *Japanese Angelica root* (*Angelica acutiloba* Kitagawa, Umbelliferae); *Bupleurum root* (*Bupleurum falcatum* Linné, Umbelliferae); and *Glycyrrhiza* (*Glycyrrhiza uralensis* Fisher, Leguminosae). To date, various ingredients responsible for the neuropsychopharmacological actions of YKS have been identified ([@B36]; [@B70]).

Yokukansan is currently used clinically to treat behavioral and psychological symptoms associated with dementia (BPSD), such as hallucinations, agitation, and aggressiveness in patients with Alzheimer's disease, dementia with Lewy bodies, vascular dementia, and other forms of senile dementia; it has been demonstrated to be an effective and well-tolerated treatment for patients with BPSD without severe adverse effects ([@B40], [@B39]; [@B73]; [@B75]; [@B86]; [@B79]; [@B67]). *In vivo* and *in vitro* basic research conducted to clarify the efficacy and mechanisms of YKS have demonstrated that it ameliorates various symptoms, including cognitive deficits, BPSD-like behaviors, and non-BPSD-like behaviors (e.g., tardive dyskinesia, neuropathic pain, allergy, morphine tolerance, and physical dependency) ([@B70]). Additionally, regulatory effects on multiple neurotransmitter systems, including glutamatergic, serotonergic, cholinergic, dopaminergic, adrenergic, and gamma-aminobutyric acid (GABA)ergic neurons are suggested to be the neuropharmacological mechanisms underlying the efficacy of YKS ([@B36]). Moreover, brain regions (e.g., cerebral cortex, amygdala, hippocampus, striatum, thalamus, hypothalamus, corpus callosum, medulla-pons, and spinal cord) which are related to behavioral, psychological, cognitive, or learning and memory functions, are the suggested target regions that contribute to the psychopharmacological efficacy of YKS ([@B70]).

The brain is primarily composed of two broad classes of cells: neurons and glial cells ([@B28]; [@B52]). Neurons comprise only 10% of the brain cells but are the most important cells involved in information processing (i.e., the neuronal network for processing information is formed by complex interactions and communication between the neurons) ([@B66]; [@B30]; [@B82]). On the other hand, 90% of brain cells are comprised of several types of glial cells (e.g., astrocytes, oligodendrocytes, and microglia), which perform a number of critical functions, including structural and metabolic support, as well as insulation. In addition, two-way communication between neurons and glial cells is essential for the maintenance of the axonal condition, synaptic transmission, and information processing, and thus, is required for normal functioning of the nervous system ([@B108]; [@B25]; [@B20]; [@B52]).

The fundamental cause of neurodegenerative diseases is neuronal death, which is induced by pathogenic factors, such as glutamate excitotoxicity, amyloid β (Aβ) neurotoxicity, neuroinflammation, oxidative stress, and apoptotic signaling. Therefore, one strategy to treat these diseases is via protection of neuronal death, focusing on neurons (e.g., blockade of glutamate receptors and the removal of Aβ). Additionally, recent studies have indicated the importance of the neuron-glia interaction. For example, excessive glutamate in the synaptic cleft causes excitotoxicity in post-synaptic neurons, and is taken up by astrocytes through the glutamate transporters expressed on their plasma membrane ([@B50]). This can be useful as an alternative strategy to treat various neurodegenerative diseases. Thus, pharmacological approaches that target neurons, as well as glial cells are ideal to prevent the neuronal death related to such diseases.

To date, basic research investigating the neuropsychopharmacological actions of YKS have reported the involvement of brain cells and its underlying mechanisms. These have suggested that YKS has protective and reparative effects against neuronal abnormalities ([@B101]; [@B33]; [@B48],[@B49]; [@B44], [@B45], [@B46]; [@B57]), astrocytes ([@B50], [@B47]), oligodendrocytes ([@B76]; [@B106]; [@B95]), and microglial cells ([@B23]; [@B61]). In addition, some of the active ingredients in YKS were examined regarding their permeability using an artificial blood--brain barrier (BBB) model that was constructed using endothelial cells ([@B37]; [@B97]). In this review, we summarized basic research from the last decade that demonstrates the effects of YKS on these brain cells, and discuss the current understanding of its efficacy and mechanisms.

Methodology
===========

The authors searched the term "yokukansan" in PubMed, Scopus, and ScienceDirect, and a total of 171 articles were selected and used for this review. Inclusion criteria: articles describing the cellular effects of YKS between 2005 and 2017 included in PubMed, Scopus, or ScienceDirect. Exclusion criteria: articles published in a language other than English.

Effects of YKS on Brain Cells
=============================

Neuron
------

Neurons are usually considered the most important cells in the brain. Each neuron consists of a cell body, an axon, and neurites, constructing a neural network of information via communication between neurons through the axon and neurites ([@B66]; [@B30]; [@B82]). Several neural networks are closely involved in behavioral performance, psychological status, and emotion, as well as thinking, learning, and memory. Therefore, neuronal death induced by pathogenic factors disrupts numerous brain functions. Neuronal death commonly occurs in the brains of individuals with several neurodegenerative diseases (e.g., Alzheimer's, Parkinson's, and cerebrovascular disease), and subsequently causes multiple cognitive deficits, memory impairment, and BPSD ([@B39]; [@B79]; [@B67]).

Yokukansan has been reported to ameliorate cognitive, learning, and memory disturbances, in addition to the accompanied BPSD-like behaviors in various rodent models of dementia ([@B35]; [@B65]; [@B93], [@B92]; [@B98]; [@B22]; [@B72]; [@B23]; [@B83]; [@B105]; [@B61]). As one of the mechanisms underlying these ameliorations, the neuroprotective activity of YKS has been suggested to be involved. In addition, several active ingredients have been identified, including geissoschizine methyl ether (GM), hirsuteine, hirsutine, and procyanidin B1 in *Uncaria hook*, and glycycoumarin in *Glycyrrhiza*, all of which protect glutamate-induced neuronal or PC12 cell death ([@B48],[@B49]; [@B45]) (**Figure [1](#F1){ref-type="fig"}**). Excessive glutamate induces neurotoxicity by both over-stimulating the *N*-methyl-[D]{.smallcaps}-aspartate receptor and inhibiting the cysteine/glutamate antiporter system Xc^-^ that facilitates the synthesis of antioxidant glutathione (GSH) for cytoprotection ([@B13]; [@B78]; [@B91]; [@B21]; [@B89]; [@B88]; [@B19]; [@B62]). The cytoprotective effects of YKS may involve both mechanisms, but the latter may be predominantly involved ([@B48]; [@B45]).

![Chemical structures of active ingredients included in YKS.](fphar-08-00655-g001){#F1}

The system Xc^-^ consists of two protein components: (1) the xCT protein responsible for transport activity; and (2) the 4F2 heavy chain (4F2hc) necessary for membrane localization of the heterodimer ([@B62]; [@B14]; [@B60], [@B59]). Interestingly, during the progression of cell death by over-glutamate exposure for 24 h, the gene expression of xCT and 4F2hc increased at early stage (6 h following glutamate exposure), for which no cell death was observed ([@B45]). The cell survival at this stage was thought to be due to the enhanced defense system by overexpressing system Xc^-^ genes. However, the prolonged exposure of glutamate for 24 h resulted in cell death by the breakdown of this defense system. YKS and four *Uncaria hook* ingredients (e.g., GM, hirsuteine, hirsutine, and procyanidin B1) protected glutamate-induced cell death at 24 h combined with the further enhancement of both the gene expression of xCT and 4F2hc at 6 h, and subsequent GSH production. This effect was counteracted by co-treating the system Xc^-^ inhibitor (S)-4-carboxyphenylglycine. Thus, the enhancement of system Xc^-^ gene expression by these factors has been suggested to contribute to the cytoprotective efficacy of YKS by preserving the cellular antioxidant ability ([@B45]). On the other hand, the *Glycyrrhiza* ingredient, glycycoumarin, demonstrated a potent cytoprotective effect by increasing the GSH level without the induction of the xCT or 4F2hc gene expression ([@B45]). Therefore, this aspect is thought to be the direct activator against GSH, not via system Xc^-^. The transcription factor Nrf2 for GSH synthesis may be potentially related to the direct effect of YKS ([@B7]). YKS and three *Uncaria hook* ingredients (e.g., GM, hirsuteine, and hirsutine) also inhibited cystine deficiency- or system Xc^-^ inhibitor-induced cell death by increasing the level of GSH ([@B49]). Therefore, these ingredients protected cell death by directly increasing the intracellular GSH levels even in the absence of the antiporter. The string of these experimental results suggests that GSH-mediated cytoprotection by YKS is thought to be mediated by individual ingredients by three mechanisms: (1) procyanidin B1 having GSH synthetic effect via system Xc^-^; (2) glycycoumarin having a direct GSH synthetic effect not via system Xc^-^; and (3) GM, hirsuteine, and hirsutine both exhibiting GSH synthetic effects.

In addition, YKS has been demonstrated to prevent endoplasmic reticulum (ER) stress-induced apoptosis in SK-N-SH human neuroblastoma cells and Neuro-2a mouse neuroblastoma cells by both upregulating chaperone protein GRP78/Bip expression for unfolded protein repair and inhibiting CCAAT/enhancer-binding protein (C/EBP) homologous protein (CHOP) expression for the induction of apoptosis ([@B33]). Ferulic acid in Cnidium rhizome is also suggested to be an active ingredient in YKS. Moreover, YKS inhibits Aβ oligomer-induced apoptosis in primary cultured cortical neurons by suppressing apoptosis effector caspase-3/7 activity ([@B102]; [@B44]); glycycoumarin and procyanidin B1 are presumed to contribute to this neuroprotection ([@B46]).

Yokukansan has also been reported to exert neuroplasticity-facilitating effects. YKS increased bromodeoxyuridine-labeled cells in the hippocampal dentate gyrus and prefrontal cortex in young and aged rats, respectively, suggesting that YKS enhances the neurogenesis and migration of neural stem cells ([@B101]). Similar effects have been reported in schizophrenia model Gunn rats ([@B23]). YKS also decreased accumulation of aggrecan, a major chondroitin sulfate proteoglycan, which suppresses neurite outgrowth and cell migration, in the prefrontal cortex and hippocampus of aged rats ([@B101]). In addition, YKS promoted neurite outgrowth of PC12 cells ([@B57]) or neuronal protection ([@B18]) through the activation of nerve growth factor-like phosphorylation and activation of protein kinase and lipid kinase pathways, such as extracellular signal-regulated kinase 1/2 (ERK1/2) and phosphatidylinositol 3-kinase/Akt (PI3K/Akt) ([@B104]; [@B107]; [@B10]). β-Eudesmol derived from *Atractylodes lancea* rhizome is suggested to be one of candidates involved in the observed neurotrophic effects ([@B85]; [@B57]). Taken together, these findings suggest that YKS may promote neuroplasticity via neurogenesis, including proliferation and differentiation, as well as neurite outgrowth even in the aged brain.

Recently, saikosaponin d, a major triterpenoid saponin derived from Bupleurum root, has been reported to facilitate autophagy, an important cellular process that controls cells in a normal homeostatic state by recycling nutrients to maintain cellular energy levels for cell survival via the turnover of proteins and damaged organelles ([@B110],[@B111]; [@B58]). In the future, it should be clarified whether YKS containing this ingredient participates in a phenomenon related to autophagy.

Finally, as one of the important neuropharmacological effects of YKS, the regulatory mechanisms for various neurotransmitter systems (i.e., serotonergic, glutamatergic, cholinergic, dopaminergic, adrenergic, and GABAergic systems) have been reported. These aspects have recently been reviewed (see for more information: [@B36]).

Astrocyte
---------

Cognitive deficit and BPSD are thought to be associated with the dysfunction of neural systems and neuronal degeneration in the brain. In several animal models of dementia, increased extracellular levels of glutamate have been demonstrated in the brain ([@B29]; [@B103]; [@B5]; [@B27]). It is well-known that increased glutamate levels induce the excitation of post-synaptic neurons; however, excessive glutamate exacerbates excitotoxic neuronal death ([@B13]; [@B12]). Under normal physiological conditions, glutamate neurotransmission to post-synaptic receptors is terminated by the clearance of glutamate from the synaptic cleft through its transporter proteins located on the plasma membrane of neurons and astroglial cells to prevent an overload of glutamate to neurons. In particular, astrocytes play an important role in the efficient removal of glutamate from the extracellular space via two glutamate transporters: (1) the glutamate aspartate transporter (GLAST); and (2) glutamate transporter 1 (GLT-1) ([@B43]; [@B90]). Therefore, a failure of this glutamatergic neurotransmission clearance system induces the hyper-excitation of neurons and neuronal death, which cause BPSD and cognitive deficits.

A thiamine deficiency induced memory disturbances and BPSD-like symptoms, including anxiety and aggressive behavior in rats ([@B35]; [@B34]). The severe degeneration of astrocytes and elevated extracellular glutamate were observed in their brain. These findings suggest that a thiamine deficiency increases extracellular glutamate levels by reducing the level of glutamate uptake into astrocytes through the glutamate transporters. Moreover, YKS prevented memory disturbances, BPSD-like behaviors, astrocyte degeneration, and increased glutamate levels resulting from thiamine deficiency ([@B35]). This suggests that YKS prevents these dysfunctions via an improvement of reduced glutamate uptake. Indeed, YKS ameliorated the thiamine deficiency-induced decrease in both the glutamate uptake into astrocytes *in vitro* and the concomitant reduction in the mRNA or protein expressions of GLAST and GLT-1 ([@B50]). Protein kinase C inhibition has been known to facilitate the glutamate transport activity ([@B15]; [@B26]; [@B31]). Since glycyrrhizin and 18β-glycyrrhetinic acid (GA) were shown to suppress protein kinase C activity in cultured astrocytes ([@B50], [@B47]), these ingredients are likely responsible for the ameliorative effects of YKS on the dysfunction of glutamate transport in astrocytes. More recently, YKS was demonstrated to alleviate the decrease in GLT-1 protein expression in the hippocampus of stress-maladaptive mice ([@B69]). Microautoradiography using normal rat hippocampal slices revealed that \[^3^H\]GA signals were distributed in small non-neuronal cells resembling astrocytes ([@B71]). Furthermore, an immunohistochemical analysis revealed that the immunoreactivity for 11β-hydroxysteroid dehydrogenase type-1, a defined molecule recognized by GA ([@B38]), was detected in the astrocytes of the hippocampus ([@B71]). These results suggest that the pharmacological actions of GA may be related to 11β-hydroxysteroid dehydrogenase type-1 in astrocytes. Thus, YKS is thought to control the external environment of neurons by removing excess glutamate via improvement of astrocyte dysfunction.

Oligodendrocyte
---------------

Oligodendrocytes are cells forming the myelin sheath surrounding the axons in a concentric manner within the central nervous system. It facilitates the rapid saltatory conduction of electrical impulses along the axon ([@B51]; [@B77]). In normal brains, although demyelination occurs, it is spontaneously repaired via remyelination mechanisms mediated by oligodendrocyte precursor cells (OPCs) ([@B3]). However, in patients with multiple sclerosis, this recovery process ultimately fails, and persistent demyelination with the subsequent axonal loss results in the progression of irreversible functional deficits ([@B51]; [@B68]). A similar level of demyelination has been demonstrated in the brains of aged rats ([@B55]), conditions of hypoxia ([@B2]), thiamine-deficient Wernicke's encephalopathy ([@B32]), and Alzheimer's disease ([@B113]).

We have previously demonstrated that YKS ameliorated not only memory dysfunction and BPSD-like behaviors, but also the demyelination and degeneration of oligodendrocytes in thiamine-deficient rat brain ([@B35]; [@B34]). These findings led us to speculate that the effectiveness of YKS may be related to the repair of demyelination by regulating the function of oligodendrocytes.

Consequently, to clarify whether YKS affects oligodendrocytes, the effects on the proliferation and differentiation of oligodendrocytes were directly examined using high-purity mouse cortical OPCs ([@B106]). YKS increased the number of OPCs in the proliferation stage and differentiated cells in the differentiation stage of the culture period. *Uncaria hook-*derived GM showed similar effect to that observed by YKS. This finding suggested that YKS promotes the proliferation and differentiation of oligodendrocytes, for which GM is one of active ingredients responsible for this effect.

Subsequently, [@B76] examined the effect of GM on the oligodendrocyte lineage in the medial prefrontal cortex of cuprizone-fed mice, an animal model of schizophrenia. As a result, GM treatment increased mature oligodendrocytes, but there was no effect against immature oligodendrocytes. These results suggest that GM exhibits a specific differentiation-promoting effect on OPCs and likely functions as a remyelination promoter in cuprizone mice.

Taken together, these findings suggest that *Uncaria hook*-derived alkaloid GM contained in YKS may enhance both the proliferation of OPCs and their differentiation into oligodendrocytes. Unfortunately, the mechanism of OPC lineage progression by GM has not been clarified. As a possible mechanism, we consider the involvement of extracellular signal regulated kinase pathway or protein kinase C, which is known to be related to OPC differentiation ([@B4]; [@B3]). This is due to the activation of ERK 1/2 and PI3K/Akt ([@B57]) by YKS as described in "Neuron," and the inhibition of protein kinase C activity ([@B47]) as described in "Astrocyte." A detailed examination to clarify the molecular mechanism is necessary in the future.

Microglia
---------

Microglial cells are found in all regions of the brain and spinal cord. They are mobile within the brain and proliferate when the brain is subjected to damage or infection ([@B25]). These microglial responses generally serve to minimize damage and protect the neurons. Nevertheless, the strong activation of microglia promotes tissue injury rather than repair ([@B6]; [@B8]). Several studies have suggested that the inflammation associated with activated microglia is detrimental to the survival of hippocampal neurons ([@B74]; [@B56]).

Recently, YKS has been reported to attenuate cerebral ischemia-induced microglial inflammatory response and subsequent neuronal apoptosis in the hippocampal CA1 region of gerbils ([@B61]). Moreover, YKS inhibited microglial activation, and promoted neurogenesis in the hippocampal dentate gyrus of Gunn rats ([@B23]). These results suggest that the ameliorative effect of YKS on cognitive deficits is mediated by promoting neurogenesis associated with the suppression of activated microglia. At the present time, active ingredients responsible for this YKS action remain unclear. However, YKS is included in several ingredients exerting an anti-inflammatory effect as follows: *Atractylodes lancea rhizome*-derived β-eudesmol ([@B94]), *Poria sclerotium*-derived pachymic acid ([@B84]), *Cnidium rhizome*-derived senkyunolide A and Z-ligustilide ([@B87]), *Cnidium rhizome* and *Japanese angelica root*-derived ferulic acid ([@B11]), *Uncaria hook*-derived rhynchophylline ([@B112]; [@B96]) and isorhynchophylline ([@B112]), *Bupleurum root*-derived saikosaponin a, c, d, and e ([@B64]), and *Glycyrrhiza*-derived liquiritigenin ([@B54]) and GA ([@B53]) (**Figure [1](#F1){ref-type="fig"}**). In the future, the relationship between these ingredients in relation to anti-microglial activation should be clarified.

Microglial cells also release glutamate through gap junction hemichannels when they are activated, which contribute to excitotoxic neuronal death. This is known to result in non-cell-autonomous neuronal death in neurodegenerative diseases ([@B63]). A gap junction hemichannel blocker based on GA that has astroglial glutamate uptake and anti-inflammatory effects has been demonstrated to suppress activated microglia and macrophage-mediated neuronal death in rodent models of transient ischemia brain injury ([@B99]) and experimental autoimmune encephalomyelitis ([@B41]). A similar suppressive effect of the blocker has been reported in mouse models of amyotriphic lateral sclerosis and Alzheimer's disease ([@B100]).

Endothelial Cell
----------------

Brain capillary endothelial cells interact with other neighboring cells, astrocytes, pericytes, perivascular microglia, and neurons ([@B42]; [@B17]; [@B1]; [@B9]). In particular, the cross-talk between the cells of a neurovascular unit is crucial for the formation and maintenance of a functional BBB ([@B1]; [@B114]). Recently, an artificial BBB model constructed from primary cultured rat cells, including brain microvessel endothelial cells, pericytes, and astrocytes, which mimic the anatomical condition *in vivo*, has been used for the evaluation of BBB permeability of psychopharmaceuticals ([@B81], [@B80]).

Using this model, the BBB permeability of several ingredients in YKS was examined. Among the seven alkaloids in *Uncaria hook* (i.e., GM, hirsutine, hirsuteine, rhynchophylline, isorhynchophylline, corynoxeine, and isocorynoxeine), GM was associated with the highest permeability rate at 27.3%, while the reference drug carbamazepine was 52.0% ([@B37]). Additionally, among the triterpenes (e.g., glycyrrhizin and GA) and flavonoids (e.g., liquiritin, liquiritigenin, isoliquiritn, and isoliquiritigenin) in *Glycyrrhiza*, liquiritigenin demonstrated the highest permeability rate at 33.4% ([@B97]); GA that acts on astrocytes to facilitate glutamate uptake was 13.3%. Indeed, GM and GA were detectable in the brains after an oral administration of YKS in rats ([@B37]; [@B97]). It is important to note that not all of these ingredients affected the endothelial tight junctions, whose disruption causes greater passage of molecules through the BBB, such as lipopolysaccharides ([@B16]; [@B24]; [@B109]).

Conclusion
==========

Yokukansan has been shown to ameliorate abnormal behaviors, psychological symptoms, cognitive deficits, as well as learning and memory impairment in several animal models of dementia and BPSD via multiple neuropsychopharmacological mechanisms ([@B36]; [@B70]). The brain regions responsible for these mechanisms are composed of brain cells consisting primarily of neurons and glial cells (i.e., astrocytes, oligodendrocytes, and microglial cells). In this review, we introduced the current findings related to the pharmacological effects of YKS against brain cells, which are summarized in **Figure [2](#F2){ref-type="fig"}**. Accumulated evidence suggests that YKS has neuroprotective properties that are mediated by increasing the anti-oxidant ability of neurons via enhancing system Xc^-^ function, anti-ER stress effects, and anti-apoptotic effects. YKS is also suggested to exhibit neuroplasticity-related effects, including neurogenesis and neurite outgrowth. Regarding non-neuronal cells, YKS normalizes reduced glutamate transporter function in astrocytes, which mediates removal of excess glutamate in the synaptic cleft, and protects glutamate-induced excitotoxicity for neurons. YKS is thought to play an important role in the maintenance of neuronal signal conduction by both the proliferation of OPCs and their differentiation into oligodendrocytes within the brains of individuals affected by neurodegenerative diseases. YKS also suppresses excessive activation of microglia in brains affected by inflammation, ischemia/reperfusion injury, and schizophrenic events.

![Multiple pharmacological actions of yokukansan on brain cells, as well as the responsible constituent medicinal herbs and ingredients. GSH, glutathione; GA, 18β-glycyrrhetinic acid; GM, geissoschizine methyl ether; *h, hook; l, lancea; r, rhizome; s, sclerotium*.](fphar-08-00655-g002){#F2}

As described above, accumulating evidence suggests that YKS might maintain neuronal function by comprehensively acting on neurons as well as various glial cells that surround them. **Figures [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}** present the candidates estimated to be involved in herbal medicines and the active ingredients that act on various cell types in the brain. This information facilitates our understanding of a variety of neuroprotective effects mediated by the multi-component drug, YKS, which is a useful strategy for preventing neuronal death, a fundamental cause of multiple neurodegenerative diseases.
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